Drug Profile

Epoetin alfa - Imagine Pharma

Alternative Names: PT-1

Latest Information Update: 22 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imagine Pharma
Class Antianaemics; Recombinant erythropoietins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Anaemia

Most Recent Events

22 Oct 2024 Phase-I clinical trials in Anaemia (PO), prior to October 2024 (Imagine Pharma pipeline, October 2024)
31 Oct 2023 Imagine pharma plans a phase I trial for Anaemia in USA in 2024 (PO) (Imagine Pharma pipeline, November 2023)
31 Oct 2023 PT 1 is available for licensing as of 31 Oct 2023. https://imaginepharma.com/programs/#pt-1

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com